Dec 13, 2019
AI-driven treatment approach and growing Fragile X Syndrome market size Healx Pharma has recently partnered with Boehringer Ingelheim to advance the treatment market and invest in R&D related to rare neurological disorders. Under the deal signed, Healx Artificial Intelligence (AI) drug discovery platfo...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
-Agonist.png "Toll-like Receptors Agonist")
Newsletter/Whitepaper